- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Morningside Group
BioCentury | Oct 20, 2023
Deals
Oct. 20 Quick Takes: GSK adds ADC through Hansoh deal
Plus: Abivax raises $236M in NASDAQ debut, stock falls and updates from Arcutis, Pfizer, BioMarin, Angitia, InflamaX, Euregen and Rezubio
BioCentury | Aug 25, 2022
Deals
Aug. 24 Quick Takes: EC approves BioMarin’s hemophilia A gene therapy
Plus Ovid, Gensaic in gene therapy deal and updates from Digital Diagnostics, BioInnovation Institute, Moderna, Relief and more
BioCentury | Sep 16, 2021
Product Development
Quick Takes: FDA approves Takeda’s Exkivity for NSCLC with specific mutation
Plus: an ALS reversal, Theravance downsizing, Calliditas still first in line, EU earmarks €50B for HERA and more
BioCentury | Sep 25, 2020
Finance
Sept. 24 Quick Takes: AveXis vets steer Taysha to IPO; plus Exact Sciences, Monte Rosa, OBiO, Moderna, Immetas and more
Taysha raises $157M in IPOShares of Taysha Gene Therapies Inc. (NASDAQ:TSHA) rose $4.06 (20%) to $24.06 in the CNS disorders company’s first day of trading, after it raised $157
BioCentury | Sep 13, 2019
Tools & Techniques
Enzymes aim to beat chemistry by creating longer, speedier, cleaner DNA strands
Companies are pushing the limits of DNA synthesis by turning from chemistry to enzymes
Items per page:
1 - 10 of 52